KinN Therapeutics is a privately held, preclinical service company providing preclinical solutions for novel anticancer therapies, companion diagnostics, and biomarker panels designed for clinical trials.

KinN Therapeutics is a Bergen, Norway -based biopharmaceutical company focused on preclinical service for development of novel anticancer compounds in the crossroad of small molecule inhibitors and immunotherapy.

At KinN Therapeutics we believe that the current dogma of rushing novel pharmaceuticals through inappropriate preclinical models is one of the major reasons for their limited clinical penetration. This can only be solved through multidisciplinary development of preclinical surrogates, models and diagnostic tools that more accurately mimic clinical conditions.

To this end, we tailor each individual model system to actively interrogate the clinical potential of your novel therapeutics through our fully characterized immunocompetent PDX models, companion imaging platforms and surrogate biomarker analysis. We actively collaborate with our partners to provide unprecedented preclinical analysis of your target and guidance for future entrance into clinical trial.